Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 60

1.

Presenilin-1 affects trafficking and processing of betaAPP and is targeted in a complex with nicastrin to the plasma membrane.

Kaether C, Lammich S, Edbauer D, Ertl M, Rietdorf J, Capell A, Steiner H, Haass C.

J Cell Biol. 2002 Aug 5;158(3):551-61. Epub 2002 Jul 29.

2.

Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology.

Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, Gerard C, Fraser P, Westaway D, St George-Hyslop P, Saido TC.

Neurosci Res. 2002 May;43(1):39-56.

PMID:
12074840
3.

Presenilin and nicastrin regulate each other and determine amyloid beta-peptide production via complex formation.

Edbauer D, Winkler E, Haass C, Steiner H.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8666-71. Epub 2002 Jun 4.

4.

Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease.

Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM.

Neurobiol Dis. 2002 Apr;9(3):305-18.

PMID:
11950276
5.

Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains.

Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, Younkin LH, Younkin SG, Golde TE.

Neurobiol Dis. 2002 Feb;9(1):11-23.

PMID:
11848681
6.

Clearing the brain's amyloid cobwebs.

Selkoe DJ.

Neuron. 2001 Oct 25;32(2):177-80. Review.

7.

A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease.

Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE.

Neurobiol Dis. 2001 Oct;8(5):890-9.

PMID:
11592856
8.

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease.

Golde TE, Eckman CB.

Drug Discov Today. 2001 Oct 15;6(20):1049-1055.

PMID:
11590033
9.

Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis.

Kirkitadze MD, Condron MM, Teplow DB.

J Mol Biol. 2001 Oct 5;312(5):1103-19.

10.

Compartmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts.

Riddell DR, Christie G, Hussain I, Dingwall C.

Curr Biol. 2001 Aug 21;11(16):1288-93.

11.

Lipid rafts and signal transduction.

Simons K, Toomre D.

Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. Review. Erratum in: Nat Rev Mol Cell Biol 2001 Mar;2(3):216.

PMID:
11413487
12.

Presenilins as therapeutic targets for the treatment of Alzheimer's disease.

Golde TE, Younkin SG.

Trends Mol Med. 2001 Jun;7(6):264-9. Review.

PMID:
11378516
13.

Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid.

Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K.

J Biol Chem. 2001 Jul 6;276(27):24985-90. Epub 2001 May 7.

14.

Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme.

Eckman EA, Reed DK, Eckman CB.

J Biol Chem. 2001 Jul 6;276(27):24540-8. Epub 2001 May 3.

15.

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5815-20. Epub 2001 Apr 17.

16.

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo.

Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, Keller P, Runz H, Kuhl S, Bertsch T, von Bergmann K, Hennerici M, Beyreuther K, Hartmann T.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5856-61. Epub 2001 Apr 10.

17.

Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases.

Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, Kiryu-Seo S, Kiyama H, Iwata H, Tomita T, Iwatsubo T, Saido TC.

J Biol Chem. 2001 Jun 15;276(24):21895-901. Epub 2001 Mar 6.

18.

Alzheimer's disease: genes, proteins, and therapy.

Selkoe DJ.

Physiol Rev. 2001 Apr;81(2):741-66. Review.

19.

Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains.

Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG.

EMBO Rep. 2000 Dec;1(6):530-5.

20.

Caveolae/lipid rafts in fibroblast-like synoviocytes: ectopeptidase-rich membrane microdomains.

Riemann D, Hansen GH, Niels-Christiansen L, Thorsen E, Immerdal L, Santos AN, Kehlen A, Langner J, Danielsen EM.

Biochem J. 2001 Feb 15;354(Pt 1):47-55.

Supplemental Content

Support Center